Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus

Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 4, Issue 1

Abstract

Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or in combination with sulfonylureas. Metformin was added at a dose ranging from 250 to 500 mg/day based on inadequate glycemic control. Liraglutide and metformin doses were converted from mg/day to mg/kg body weight/day before analysis of the correlation between the dose and changes in glycated hemoglobin (HbA1c) and body mass index (BMI). Results: Both HbA1c and BMI decreased significantly after 24 weeks of the combination treatment. Mild gastrointestinal adverse events were reported by 21% of the patients. Only the dose of metformin, but not that of liraglutide, expressed in mg/kg body weight was correlated significantly with decrease in HbA1c and BMI. Conclusions: The addition of metformin to the maximum permissible dose of liraglutide helps secure glycemic control and reduce BMI in Japanese patients with type 2 diabetes who exhibit inadequate response to liraglutide.

Authors and Affiliations

Masao Toyoda

Keywords

Related Articles

Gene Polymorphisms of Cytokines IFN γ +874 (A/T), TNF Α-308 (G/A), IL-6 -174 (G/C), L’il-10 -1082(A/G), -819 (C/T) -592 (C/A), TGF-β1 +869 (T /C), +915 (G/C) in Algerian Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA)

Background: We aimed to investigate the association between five cytokines IFN gamma 874 A T TNF Alpha -308 G A IL-6 -174 G C L rsquo il-10 -1082 A G -819 C T -592 C A TGF- beta 1 869 T C 91...

Determinants of Misperception of Weight Status Among a Community of Adults in the Region of Sousse, Tunisia

Aim: To determine the prevalence of misperception of body weight status among Tunisian adults in the region of Sousse and examine its associated factors. Materials and Methods: The studied population was randomly selecte...

Rapid Perioperative Changes in the Quantitative Properties of Plasma Lipases and Lipoproteins in Morbidly Obese Surgical Patients

Background: The impact of bariatric surgery on abnormalities in blood lipids and lipoprotein metabolism during the perioperative period has been poorly studied. Objective: We studied the impact of bariatric surgery on th...

Composition Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes

Association between type 2 diabetes (T2DM) and compositional changes in the gut micro biota is established, however little is known about the dysbiosis in early stages of Prediabetes (preDM). The purpose of this investig...

Factors associated with metabolic syndrome in patients with mental disorders in Mexico.

Background: Metabolic syndrome (MS) is a public health problem globally and nationally, with a prevalence of up to 26%; associated with mental disorders, the magnitude and chronicity may be increased. Methods: We carried...

Download PDF file
  • EP ID EP417851
  • DOI 10.15436/2376-0494.17.1300
  • Views 118
  • Downloads 0

How To Cite

Masao Toyoda (2016). Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes and Obesity, 4(1), 0-0. https://europub.co.uk/articles/-A-417851